--- title: "Pre-market hot trades in US stocks: Nebius pre-market down 5.48%; Applied Optoelectronics pre-market down 5.34%" type: "News" locale: "en" url: "https://longbridge.com/en/news/281528853.md" description: "Nebius pre-market down 5.48%; Applied Optoelectronics pre-market down 5.34%; Sky Quarry pre-market up 136.29%; TMD Energy pre-market up 62.26%; Cocrystal Pharma pre-market up 56.86%" datetime: "2026-04-02T13:03:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281528853.md) - [en](https://longbridge.com/en/news/281528853.md) - [zh-HK](https://longbridge.com/zh-HK/news/281528853.md) --- # Pre-market hot trades in US stocks: Nebius pre-market down 5.48%; Applied Optoelectronics pre-market down 5.34% **Pre-market Hot Trades in US Stocks** Nebius is down 5.48% in pre-market trading. Based on recent key news: 1. On March 31, Nebius announced plans to establish a 310 MW AI factory in Lappeenranta, Finland. This news drove the company's stock price up 6.57% to $98.26. The factory is expected to create 700 construction jobs and 100 permanent positions. Source: Press Release 2. On March 31, Nebius reached a partnership with Nvidia, with Nvidia investing $2 billion to deploy over 5 GW of AI systems. This news further boosted market confidence and drove the stock price up. Source: Press Release 3. On March 31, analysts generally have a positive outlook on Nebius. B of A Securities and DA Davidson both gave buy ratings, setting target prices at $150 and $200, respectively. Source: Benzinga Pro. The AI industry is expanding rapidly, and investor sentiment is high. Applied Optoelectronics is down 5.34% in pre-market trading. Based on recent key news: 1. On March 31, Applied Optoelectronics showcased its 6.4T OBO high-density integrated photonics demonstration at OFC, a key advancement for AI networks. This technology provides high-density solutions for hyperscale AI infrastructure, supporting the extreme throughput demands of modern GPU architectures, influencing stock price volatility. 2. On March 31, Applied Optoelectronics announced it received an 800G order totaling over $53 million. This order is expected to support customers' large-scale infrastructure expansion plans, and the confirmation of the order and upcoming shipping plans have a positive impact on the market. 3. On March 31, Applied Optoelectronics partnered with Oxford Instruments to enhance its InP-based photonic device manufacturing capabilities. This collaboration helps strengthen the company's competitiveness in the photonics field, further influencing stock prices. The demand for AI networks is growing, and the industry outlook is optimistic. **Top Gainers in Pre-market US Stocks** Sky Quarry is up 136.29% in pre-market trading. Based on recent news: 1. On April 2, Sky Quarry's Nevada refinery gained strategic value as Brent crude oil prices surpassed $110 and West Coast refining capacity was reduced. This news significantly boosted Sky Quarry's stock price. 2. On April 2, Sky Quarry Inc. released related content through ACCESS Newswire, further confirming the strategic importance of its Nevada refinery and enhancing market confidence. 3. On March 30, the U.S. Securities and Exchange Commission released documents regarding Sky Quarry, providing more company information and increasing investor confidence in its future development The rise in crude oil prices and the reduction in refining capacity are affecting the market. TMD Energy is up 62.26% in pre-market trading. There has been no significant news recently; trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no\_news Cocrystal Pharma is up 56.86% in pre-market trading. Based on recent news, 1. On April 2, the U.S. Food and Drug Administration (FDA) granted Cocrystal Pharma's CDI-988 Fast Track designation for the treatment and prevention of norovirus infections. This news significantly boosted the company's stock price. 2. On March 31, Cocrystal Pharma announced its financial results for fiscal year 2025, showing a basic earnings per share of -$0.78 and an operating loss of $9.02 million. Despite the poor financial data, the market remains optimistic about its new drug development prospects. 3. On April 2, Cocrystal Pharma announced that its CDI-988 is undergoing a Phase 1b randomized, double-blind, placebo-controlled challenge study at Emory University, further enhancing market confidence in its new drug. The biopharmaceutical industry has performed strongly recently, and investors are focused on new drug development progress ### Related Stocks - [NBIS.US](https://longbridge.com/en/quote/NBIS.US.md) - [AAOI.US](https://longbridge.com/en/quote/AAOI.US.md) ## Related News & Research - [Applied Optoelectronics jumps after hyperscaler more than doubles its recent order](https://longbridge.com/en/news/281759169.md) - [Nebius Stock: A Hidden AI Gem or Too Risky to Touch?](https://longbridge.com/en/news/281789024.md) - [AOI Receives New Upsized Order for 800G Data Center Transceivers from Major Hyperscale Customer | AAOI Stock News](https://longbridge.com/en/news/281570498.md) - [CoreWeave and Nebius Have Outperformed Every "Magnificent Seven" Artificial Intelligence (AI) Stock This Year. Can It Last?](https://longbridge.com/en/news/282048921.md) - [Nebius Insiders Sold Shares Worth Over $4M](https://longbridge.com/en/news/281429849.md)